Home/Pipeline/TLR-006

TLR-006

Chronic Pain

Phase 2Active

Key Facts

Indication

Chronic Pain

Phase

Phase 2

Status

Active

Company

Tilray

About Tilray

Tilray's mission is to be the world's leading cannabis-focused consumer branded goods and pharmaceutical company. Its key achievements include establishing one of the largest global footprints in cannabis cultivation and distribution, successfully merging with Aphria to create an industry leader, and building a clinical pipeline targeting serious conditions like glioblastoma and epilepsy. The company's strategy is to drive growth through its diversified portfolio—spanning cannabis, beverage alcohol, and wellness products—while investing in high-value pharmaceutical R&D to unlock long-term value from cannabinoid science.

View full company profile

Therapeutic Areas

Oncology Neurology Inflammatory Conditions

Other Chronic Pain Drugs

Drug	Company	Phase	Status
SCI-160	SciSparc	Preclinical	Active
Injectrode Platform for Chronic Pain	Neuronoff	Pre-clinical	Active
Novel PNS System	Nervonik	First-in-Human Completed	Active
Pain Pipeline	Centrexion Therapeutics	Clinical Stage	Active
High-Definition Spinal Cord Stimulation	Micro-Leads	Unknown	Active
Precision Medicine for Pain	MindX Sciences	Commercial	Active
Chronic Pain Program	Current Surgical	Research	Active
N-19a	Neurocarrus	Pre-clinical	Active
Nav1.7 ASO	Quiver Bioscience	Discovery	Active
Nav1.8 ASO	Quiver Bioscience	Discovery	Active
Dual Nav1.7/1.8 ASO	Quiver Bioscience	Discovery	Active
TMS for Chronic Pain	Magstim	Commercial/Clinical Development	Active